• PDF / 170,553 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 45 Downloads / 199 Views

DOWNLOAD

REPORT

---

1

S

Various toxicities: 7 case reports In a retrospective study of nine patients, 7 patients (3 men and 4 women) aged 52–85 years were described, who developed chills, aching of limbs, eczema, peripheral neuropathy, neutropenia, muscle cramps, nausea, erysipelas, fever, asthma or vomiting during treatment with aldesleukin and unspecified programmed-cell-death-1-receptorantagonist for metastatic melanoma [dosages and time to reactions onsets not stated]. The patients, who had metastatic melanoma, received monotherapy with unspecified programmed-celldeath-1-receptor-antagonist. However, the patients developed progressive disease. Hence, the patients started receiving combination therapy with intralesional aldesleukin [Proleukin] and unspecified programmed-cell-death-1-receptorantagonist. Aldesleukin was freshly prepared by diluting it to 5% of glucose solution to achieve a final concentration of 3 MIU of aldesleukin per milliliter. In one treatment session, a maximum of 9 MIU (3 ml) per patient was injected in the cutaneous lesions. Subsequently, the patients developed combination therapy-related side effects including chills and aching limbs (one patient), chills and eczema (one patient), grade 3 peripheral neuropathy and dysesthesia, grade 2 neutropenia, and muscle cramps (one patient), nausea and erysipelas (one patient), fever and asthma (one patient), fever, chills and vomiting (one patient) and fever (one patient). The side effects were well controlled with unspecified nonsteroidal-anti-inflammatories treatment. Of these 7 patients, 2 patients discontinued aldesleukin due to disease progression and one patient temporary discontinued aldesleukin due to therapy-related side effects. Author comment: "Combination therapy was generally well tolerated. Most frequent side effects were low grade and transient (chills, aching limbs and fever) (Table 1) and were well controlled with non-steroidal anti-inflammatory drugs (NSAIDs). One patient suffered from peripheral polyneuropathy with dysesthesia [Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 grade 3] as well as a reversible neutropenia (CTCAE grade 2) which lead to a temporary discontinuation of IL-2 treatment." Rafei-Shamsabadi D, et al. Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. Cancer Immunology Immunotherapy 68: 1417-1428, No. 9, Sep 2019. Available from: URL: http:// 803435682 doi.org/10.1007/s00262-019-02377-x - Germany

0114-9954/19/1780-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved

Reactions 23 Nov 2019 No. 1780